Navigation Links
Study using stem cells to improve organ transplantation to receive $12 million
Date:11/7/2013

CHICAGO An innovative Northwestern Medicine research program investigating if stem cells may be the key to allowing organ transplant patients to stop taking immunosuppressive drugs has received $12 million in research funding. The grant will allow researchers to finish Phase II of the clinical trials and begin Phase III. Northwestern began the study's clinical trial in early 2009 as part of a partnership with the University of Louisville, which engineers the specialized stem cells used in each transplant procedure.

"During our clinical trials, we have been able to take the novel stem cell technology that the University of Louisville pioneered from the bench to the bedside," said Joseph Leventhal, MD PhD, director of kidney and pancreas transplantation at Northwestern Memorial Hospital, and professor of Surgery at Northwestern University Feinberg School of Medicine. "The results of our clinical trial were a catalyst for Novartis' long-term investment in this new cellular based therapy for solid organ transplantation."

The clinical trial uses specially engineered stem cells from kidney donors to make the organ recipient's immune system recognize the new kidney as its own. In mainstream transplant procedures, a recipient faces the danger of their immune system treating a newly transplanted organ as a foreign body that should be removed, causing it to attack and try to kill the new organ. To prevent a recipient's immune system from attacking their new organ, doctors must currently prescribe toxic anti-rejection medicines to weaken the immune system and keep it at bay.

In March of 2012, Leventhal and his colleagues published the study's initial clinical results from eight participants in Science Translational Medicine. The article outlined that of the study's eight participants, five were able to successfully stop taking all anti-rejection medicines in just one year after they received a new kidney, and two required only low-doses of anti-rejection medicine to be maintained instead of a normal regimen. The final patient suffered an unrelated illness that required another kidney transplant to be performed.

"Northwestern's Comprehensive Transplant Center has demonstrated for the first time in the history of organ transplantation that we can safely achieve durable transplantation tolerance in mismatched and unrelated donor/recipient combinations," said Leventhal. "I am very excited to be able to continue this groundbreaking translational research."

The first subjects to participate in the research study underwent surgery on February 26, 2009. To date, more than 20 patients have been enrolled and have received new kidneys as part of the clinical trial, the majority of which have been successfully taken off of all anti-rejection medicines. In order to qualify, the donor and recipient pairs must be blood-type compatible and have a negative cross-match, which means that testing has been done to confirm the recipient does not have antibodies in the blood that would cause rejection of the kidney.

The grant is a result of a license and research collaboration agreement between Regenerex LLC and Novartis to provide access to the novel technology developed by the University of Louisville's Institute for Cellular Therapeutics. Leventhal does not receive financial incentives or payment from Novartis or Regenerex LLC.


'/>"/>

Contact: Bret Coons
bcoons@nmh.org
312-926-2955
Northwestern Memorial Hospital
Source:Eurekalert

Related medicine news :

1. FDA awards $2.25M grant to study immunosuppresive drug in high-risk patients
2. Study finds that Americans want doctors guidance on genetic test results
3. New study assesses injuries seen in the emergency department to children of teenage parents
4. Study Finds Infants Under 6 Months Too Young for Flu Shot at High Risk to Influenza Fatalities- UV Technologies Makers of UV-Aid, Develop New Flu Prevention Alternative
5. Independent Naturopathic Clinic Receives Groundbreaking Research Grant: Partners with Global Pharmaceutical Company to Study Relief of Cancer Drug Side Effects
6. 20 percent of nations GME funds go to New York while 29 states get less than 1 percent, study says
7. Physician shortage could be cut by new primary care models, study finds
8. Study: Access to health care increases prescription opioid availability and associated abuse
9. Study: Higher rates of diabetes, hypertension, heart disease and stroke found in food desert
10. U-M study: Smarter blood pressure guidelines could prevent many more heart attacks and strokes
11. Study looks at safety, effectiveness of generics for treating depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... ... 18, 2017 , ... President Donald Trump signed into law ... for greater public access to over-the-counter (OTC) hearing aids. , The measure enables ... without being seen by a certified and licensed audiologist. , “The American ...
(Date:8/19/2017)... ... August 19, 2017 , ... ... a diverse community of over 1,000 passionate employees, caregivers, volunteers, thought leaders, researchers, ... at Stonegate changed ownership, it was time to refresh the carpeting with the ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... Immediate Release                Contact: Julian Teixeira, August 18, 2017                    202-478-8564 / jteixeira@thenc.org , ... from their Fathers , Contrary to a father’s perception, ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... liquid handling handheld devices. Through an educational webinar, they will present the line ... a chance to learn how easy you can automate everyday pipetting tasks. , ...
(Date:8/18/2017)... ... 18, 2017 , ... MLM Insurance Group, a Miami area ... Florida, is working to support the Take Stock In Children Foundation during a ... , The Take Stock In Children Foundation (TSC) offers guidance and assistance to ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Mich. , Aug. 15, 2017 Diplomat ... naloxone to Michigan residents. ... Flint retail pharmacy, G-3320 Beecher ... approved by the Food and Drug Administration, is intended ... extreme drowsiness, slowed breathing, and loss of consciousness. The ...
(Date:8/11/2017)... 11, 2017 DarioHealth Corp. (NASDAQ: DRIO), a ... big data solutions, today announced that it will release ... and host a conference call at 9:00am ET. The ... financial results and its strategy and outlook for the ... Erez Raphael , Chief Executive Officer, and ...
(Date:8/7/2017)... Aug. 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that its Board of Directors has approved the payment ... quarter of 2017. The ... or about October 27, 2017 to stockholders of record as ... declarations of dividends are subject to approval of the Board ...
Breaking Medicine Technology: